TAE-1 |
Catalog No.GC17007 |
inhibitor of amyloid-β fibril formation and aggregation
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1414469-59-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 0.3 ± 0.02 μM for AChE; 3.9 ± 0.2 μM for BuChE
TAE-1 is an inhibitor of amyloid-β fibril formation and aggregation.
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by the cerebral accumulation of insoluble aggregates of amyloid-β peptides (Aβ). Although the precise mechanisms governing neuronal loss remains ambiguous, toxicity resulting from Aβ-activated pathways is evident.
In vitro: In a previous study, the authors examined the effects of TAE-1 on differentiated human SH-SY5Y neuronal cells grown in tissue culture. Results showed that the stimulation of neuronal cellular process length and branching was noted. Moreover, the increased synaptophysin suggested that TAE-1 could stimulate synapse formation. Increased expression of MAP2 was also observed, indicating that TAE-1 promoted the differentiation of human neurons. In addition, targeted AChE inhibition was evaluated by electrochemical quantification of the enzymatic product, thiocholine, on unmodified gold screen-printed electrodes. It was found that at increasing TAE-1concentrations, there was a corresponding decrease in the AChE activity resulting in reduced amount of oxidizable thiocholine. The IC50 value was found to be 0.465 μM for TAE-1 [1].
In vivo: Up to now, there is no animla in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Veloso AJ, Chow AM, Dhar D, Tang DW, Ganesh HV, Mikhaylichenko S, Brown IR, Kerman K. Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease. ACS Chem Neurosci. 2013 Jun 19;4(6):924-9.
Cas No. | 1414469-59-2 | SDF | |
Chemical Name | 2,2',2'-[1,3,5-triazine-2,4,6-triyltris(oxy-4,1-phenylenecarbonyloxy)]tris[N,N,N-trimethyl-ethanaminium]triiodide | ||
Canonical SMILES | O=C(OCC[N+](C)(C)C)C(C=C1)=CC=C1OC2=NC(OC3=CC=C(C(OCC[N+](C)(C)C)=O)C=C3)=NC(OC4=CC=C(C(OCC[N+](C)(C)C)=O)C=C4)=N2.[I-].[I-].[I-] | ||
Formula | C39H51N6O9 • 3I | M.Wt | 1128.6 |
Solubility | Acetonitrile: 5 mg/ml,DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: Partially soluble,PBS (pH 7.2): 5 mg/ml | Storage | Store at 2°C to 8°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8861 mL | 4.4303 mL | 8.8605 mL |
5 mM | 0.1772 mL | 0.8861 mL | 1.7721 mL |
10 mM | 0.0886 mL | 0.443 mL | 0.8861 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 24 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *